Jeffrey Swigris
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Idiopathic Pulmonary Fibrosis | 67 | 2025 | 697 | 11.630 |
Why?
| | Lung Diseases, Interstitial | 63 | 2026 | 677 | 10.640 |
Why?
| | Dyspnea | 29 | 2026 | 251 | 6.520 |
Why?
| | Quality of Life | 48 | 2026 | 3187 | 6.010 |
Why?
| | Pulmonary Fibrosis | 26 | 2025 | 395 | 5.430 |
Why?
| | Cough | 10 | 2024 | 123 | 3.520 |
Why?
| | Oxygen Inhalation Therapy | 13 | 2021 | 189 | 3.250 |
Why?
| | Vital Capacity | 34 | 2026 | 293 | 3.030 |
Why?
| | Surveys and Questionnaires | 39 | 2026 | 6050 | 2.940 |
Why?
| | Alveolitis, Extrinsic Allergic | 7 | 2026 | 96 | 2.730 |
Why?
| | Connective Tissue Diseases | 13 | 2019 | 85 | 2.240 |
Why?
| | Arthritis, Rheumatoid | 13 | 2026 | 1184 | 1.810 |
Why?
| | Lymphangioleiomyomatosis | 6 | 2024 | 37 | 1.700 |
Why?
| | Pyridones | 12 | 2023 | 210 | 1.610 |
Why?
| | Patient Reported Outcome Measures | 7 | 2024 | 502 | 1.480 |
Why?
| | Severity of Illness Index | 21 | 2026 | 2910 | 1.470 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 11 | 2021 | 344 | 1.450 |
Why?
| | Patient Outcome Assessment | 3 | 2021 | 128 | 1.380 |
Why?
| | Sarcoidosis | 5 | 2021 | 164 | 1.330 |
Why?
| | Indoles | 6 | 2024 | 509 | 1.330 |
Why?
| | Humans | 168 | 2026 | 145625 | 1.280 |
Why?
| | Aged | 71 | 2026 | 26251 | 1.250 |
Why?
| | Middle Aged | 83 | 2026 | 36359 | 1.220 |
Why?
| | Pulmonary Medicine | 3 | 2022 | 78 | 1.190 |
Why?
| | Lung | 21 | 2024 | 4119 | 1.190 |
Why?
| | Psychometrics | 11 | 2026 | 708 | 1.170 |
Why?
| | Fatigue | 9 | 2024 | 362 | 1.140 |
Why?
| | Walking | 7 | 2013 | 544 | 1.080 |
Why?
| | Respiratory Function Tests | 19 | 2025 | 543 | 1.070 |
Why?
| | Oxygen | 7 | 2023 | 996 | 0.980 |
Why?
| | Male | 92 | 2026 | 73014 | 0.950 |
Why?
| | Patients | 3 | 2018 | 183 | 0.950 |
Why?
| | Reproducibility of Results | 19 | 2026 | 3396 | 0.950 |
Why?
| | Tomography, X-Ray Computed | 20 | 2025 | 2766 | 0.940 |
Why?
| | Hypertension, Pulmonary | 6 | 2023 | 1957 | 0.920 |
Why?
| | Female | 95 | 2026 | 79080 | 0.920 |
Why?
| | Health Care Costs | 3 | 2018 | 418 | 0.900 |
Why?
| | Exercise Test | 9 | 2024 | 634 | 0.900 |
Why?
| | Research Design | 5 | 2016 | 1139 | 0.890 |
Why?
| | Health Status Indicators | 4 | 2014 | 166 | 0.890 |
Why?
| | Patient-Centered Care | 2 | 2021 | 551 | 0.850 |
Why?
| | Activities of Daily Living | 6 | 2022 | 438 | 0.840 |
Why?
| | Disease Progression | 20 | 2025 | 2857 | 0.830 |
Why?
| | Exercise Tolerance | 4 | 2020 | 288 | 0.780 |
Why?
| | Mycophenolic Acid | 4 | 2016 | 117 | 0.730 |
Why?
| | Forced Expiratory Volume | 12 | 2023 | 451 | 0.710 |
Why?
| | Idiopathic Interstitial Pneumonias | 7 | 2026 | 44 | 0.680 |
Why?
| | Internet | 2 | 2016 | 656 | 0.680 |
Why?
| | Organizational Objectives | 1 | 2021 | 67 | 0.670 |
Why?
| | Autoimmune Diseases | 5 | 2026 | 466 | 0.660 |
Why?
| | Nursing Research | 1 | 2021 | 49 | 0.660 |
Why?
| | Patient Satisfaction | 3 | 2021 | 698 | 0.660 |
Why?
| | Caregivers | 4 | 2019 | 1079 | 0.640 |
Why?
| | Pulmonary Emphysema | 2 | 2024 | 276 | 0.620 |
Why?
| | Lactic Acid | 1 | 2022 | 295 | 0.620 |
Why?
| | Rhinitis, Allergic | 1 | 2020 | 41 | 0.600 |
Why?
| | Undifferentiated Connective Tissue Diseases | 1 | 2019 | 1 | 0.590 |
Why?
| | Symptom Assessment | 1 | 2020 | 137 | 0.590 |
Why?
| | Chronic Disease | 5 | 2022 | 1824 | 0.590 |
Why?
| | Prognosis | 17 | 2026 | 4331 | 0.580 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2022 | 926 | 0.570 |
Why?
| | Fatty Acids | 1 | 2022 | 460 | 0.550 |
Why?
| | Emphysema | 1 | 2018 | 100 | 0.520 |
Why?
| | Patient Education as Topic | 3 | 2019 | 769 | 0.500 |
Why?
| | Particulate Matter | 1 | 2020 | 328 | 0.500 |
Why?
| | Needs Assessment | 2 | 2019 | 403 | 0.490 |
Why?
| | Longitudinal Studies | 9 | 2020 | 3005 | 0.480 |
Why?
| | Lung Diseases | 3 | 2015 | 787 | 0.480 |
Why?
| | Pulmonary Diffusing Capacity | 7 | 2019 | 78 | 0.470 |
Why?
| | Aged, 80 and over | 19 | 2021 | 8351 | 0.470 |
Why?
| | Heart Rate | 2 | 2011 | 844 | 0.470 |
Why?
| | Immunosuppressive Agents | 4 | 2016 | 824 | 0.460 |
Why?
| | Lung Transplantation | 1 | 2019 | 326 | 0.450 |
Why?
| | Air Pollutants | 1 | 2020 | 406 | 0.450 |
Why?
| | Qualitative Research | 4 | 2017 | 1720 | 0.450 |
Why?
| | Information Seeking Behavior | 1 | 2016 | 39 | 0.450 |
Why?
| | United States | 25 | 2024 | 16041 | 0.450 |
Why?
| | Treatment Outcome | 20 | 2023 | 11744 | 0.450 |
Why?
| | Myositis | 4 | 2025 | 57 | 0.450 |
Why?
| | Gastroesophageal Reflux | 2 | 2021 | 232 | 0.440 |
Why?
| | Exercise | 4 | 2022 | 2206 | 0.430 |
Why?
| | Adult | 39 | 2024 | 40821 | 0.430 |
Why?
| | Narration | 1 | 2016 | 82 | 0.420 |
Why?
| | Double-Blind Method | 10 | 2024 | 2064 | 0.420 |
Why?
| | Ambulatory Care | 2 | 2018 | 627 | 0.420 |
Why?
| | Mental Health | 2 | 2020 | 771 | 0.410 |
Why?
| | Kaplan-Meier Estimate | 8 | 2018 | 959 | 0.410 |
Why?
| | Autoantibodies | 6 | 2023 | 1498 | 0.400 |
Why?
| | Retrospective Studies | 27 | 2025 | 17291 | 0.400 |
Why?
| | Autoimmunity | 2 | 2019 | 924 | 0.400 |
Why?
| | Telemedicine | 1 | 2023 | 956 | 0.400 |
Why?
| | Antibodies, Monoclonal | 1 | 2021 | 1511 | 0.390 |
Why?
| | Biomedical Research | 2 | 2018 | 724 | 0.390 |
Why?
| | Antitussive Agents | 1 | 2013 | 7 | 0.380 |
Why?
| | Social Media | 1 | 2016 | 158 | 0.380 |
Why?
| | Bronchiolitis Obliterans | 1 | 2013 | 59 | 0.380 |
Why?
| | Thalidomide | 1 | 2013 | 43 | 0.370 |
Why?
| | Lung Neoplasms | 4 | 2024 | 2674 | 0.370 |
Why?
| | Social Support | 2 | 2019 | 644 | 0.360 |
Why?
| | Motivation | 1 | 2017 | 601 | 0.360 |
Why?
| | Physicians | 2 | 2019 | 954 | 0.360 |
Why?
| | Survival Rate | 7 | 2019 | 2078 | 0.360 |
Why?
| | Bronchial Diseases | 1 | 2012 | 38 | 0.360 |
Why?
| | Prospective Studies | 10 | 2026 | 8087 | 0.350 |
Why?
| | Patient Participation | 1 | 2015 | 454 | 0.340 |
Why?
| | Follow-Up Studies | 9 | 2018 | 5397 | 0.340 |
Why?
| | Quality Indicators, Health Care | 1 | 2014 | 340 | 0.330 |
Why?
| | Oxygen Consumption | 3 | 2022 | 719 | 0.330 |
Why?
| | Scleroderma, Systemic | 4 | 2019 | 123 | 0.330 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 1403 | 0.320 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1531 | 0.320 |
Why?
| | Health Status | 5 | 2019 | 822 | 0.310 |
Why?
| | Peptides, Cyclic | 1 | 2012 | 276 | 0.310 |
Why?
| | Motor Activity | 1 | 2014 | 701 | 0.300 |
Why?
| | Asthma | 2 | 2020 | 1800 | 0.300 |
Why?
| | Endothelins | 1 | 2010 | 61 | 0.300 |
Why?
| | Protein Kinase Inhibitors | 3 | 2021 | 982 | 0.300 |
Why?
| | Hospitalization | 3 | 2017 | 2468 | 0.300 |
Why?
| | Cause of Death | 6 | 2019 | 455 | 0.290 |
Why?
| | Diagnosis, Differential | 7 | 2019 | 1500 | 0.290 |
Why?
| | Pulmonologists | 2 | 2019 | 14 | 0.280 |
Why?
| | Pulmonary Embolism | 1 | 2011 | 245 | 0.280 |
Why?
| | Endothelin-1 | 1 | 2010 | 177 | 0.280 |
Why?
| | TRPP Cation Channels | 1 | 2009 | 76 | 0.280 |
Why?
| | Proportional Hazards Models | 4 | 2019 | 1318 | 0.270 |
Why?
| | Amino Acyl-tRNA Synthetases | 3 | 2016 | 32 | 0.270 |
Why?
| | Cohort Studies | 8 | 2025 | 6045 | 0.270 |
Why?
| | Registries | 4 | 2025 | 2382 | 0.270 |
Why?
| | Polycystic Kidney Diseases | 1 | 2009 | 82 | 0.260 |
Why?
| | Randomized Controlled Trials as Topic | 6 | 2021 | 1754 | 0.260 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2012 | 300 | 0.260 |
Why?
| | Sirolimus | 2 | 2023 | 282 | 0.250 |
Why?
| | Vascular Endothelial Growth Factor D | 3 | 2023 | 13 | 0.240 |
Why?
| | Biopsy | 7 | 2016 | 1073 | 0.240 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2025 | 641 | 0.240 |
Why?
| | Sex Distribution | 3 | 2012 | 379 | 0.240 |
Why?
| | Tumor Suppressor Proteins | 1 | 2009 | 314 | 0.240 |
Why?
| | Home Care Services | 2 | 2020 | 290 | 0.230 |
Why?
| | Mortality | 4 | 2019 | 375 | 0.230 |
Why?
| | Prevalence | 5 | 2018 | 2852 | 0.230 |
Why?
| | Exercise Therapy | 3 | 2024 | 486 | 0.230 |
Why?
| | Cost of Illness | 3 | 2018 | 322 | 0.230 |
Why?
| | Palliative Care | 3 | 2019 | 1032 | 0.230 |
Why?
| | Patient Advocacy | 2 | 2024 | 73 | 0.230 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2008 | 240 | 0.220 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2025 | 121 | 0.220 |
Why?
| | Quality Improvement | 1 | 2014 | 1325 | 0.210 |
Why?
| | Fibrosis | 2 | 2024 | 568 | 0.200 |
Why?
| | Minimal Clinically Important Difference | 2 | 2021 | 35 | 0.200 |
Why?
| | Thrombosis | 1 | 2008 | 397 | 0.200 |
Why?
| | Age Distribution | 3 | 2019 | 395 | 0.190 |
Why?
| | Time Factors | 7 | 2019 | 7079 | 0.190 |
Why?
| | Databases, Factual | 3 | 2019 | 1481 | 0.190 |
Why?
| | Evidence-Based Medicine | 2 | 2020 | 727 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 347 | 0.180 |
Why?
| | Respiratory Therapy | 2 | 2019 | 25 | 0.180 |
Why?
| | Sex Factors | 6 | 2019 | 2101 | 0.180 |
Why?
| | Environmental Exposure | 2 | 2020 | 578 | 0.170 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2021 | 40 | 0.170 |
Why?
| | Risk Factors | 9 | 2026 | 10840 | 0.170 |
Why?
| | Patient Care Management | 1 | 2021 | 54 | 0.160 |
Why?
| | Incidence | 3 | 2018 | 2910 | 0.160 |
Why?
| | Analysis of Variance | 3 | 2015 | 1293 | 0.160 |
Why?
| | Linear Models | 3 | 2019 | 847 | 0.160 |
Why?
| | Survival Analysis | 3 | 2017 | 1372 | 0.150 |
Why?
| | Interleukin-13 | 1 | 2021 | 149 | 0.150 |
Why?
| | Logistic Models | 4 | 2019 | 2112 | 0.150 |
Why?
| | Antibodies, Antinuclear | 4 | 2016 | 60 | 0.150 |
Why?
| | Pain Measurement | 1 | 2022 | 567 | 0.150 |
Why?
| | Walk Test | 2 | 2017 | 82 | 0.150 |
Why?
| | Focus Groups | 3 | 2016 | 587 | 0.150 |
Why?
| | Sensitivity and Specificity | 3 | 2015 | 1992 | 0.150 |
Why?
| | Chi-Square Distribution | 2 | 2011 | 511 | 0.140 |
Why?
| | General Practitioners | 1 | 2019 | 26 | 0.140 |
Why?
| | Allied Health Personnel | 1 | 2019 | 54 | 0.140 |
Why?
| | Immunoglobulin A | 1 | 2019 | 205 | 0.140 |
Why?
| | Insurance Claim Review | 1 | 2018 | 85 | 0.140 |
Why?
| | Terminal Care | 2 | 2019 | 284 | 0.130 |
Why?
| | Lipid Metabolism | 1 | 2022 | 533 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2022 | 1075 | 0.130 |
Why?
| | Accelerometry | 2 | 2019 | 123 | 0.130 |
Why?
| | Anxiety | 3 | 2019 | 1118 | 0.130 |
Why?
| | Attitude to Health | 2 | 2014 | 419 | 0.130 |
Why?
| | Physician Assistants | 1 | 2019 | 101 | 0.120 |
Why?
| | Weight-Bearing | 1 | 2018 | 186 | 0.120 |
Why?
| | Cellular Senescence | 1 | 2019 | 225 | 0.120 |
Why?
| | Allergens | 1 | 2020 | 390 | 0.120 |
Why?
| | Cross-Sectional Studies | 4 | 2019 | 5875 | 0.120 |
Why?
| | Inflammation | 2 | 2025 | 2915 | 0.120 |
Why?
| | Germany | 1 | 2017 | 139 | 0.120 |
Why?
| | Nurse Practitioners | 1 | 2019 | 141 | 0.120 |
Why?
| | Nurses | 1 | 2019 | 171 | 0.120 |
Why?
| | Common Variable Immunodeficiency | 1 | 2016 | 26 | 0.120 |
Why?
| | Perception | 1 | 2019 | 372 | 0.120 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 366 | 0.120 |
Why?
| | Sulfonamides | 2 | 2010 | 592 | 0.120 |
Why?
| | Antihypertensive Agents | 2 | 2010 | 519 | 0.120 |
Why?
| | Tidal Volume | 1 | 2016 | 108 | 0.120 |
Why?
| | Granuloma | 1 | 2016 | 96 | 0.120 |
Why?
| | Cyclophosphamide | 1 | 2016 | 275 | 0.110 |
Why?
| | Medicare | 2 | 2018 | 907 | 0.110 |
Why?
| | Muscle Strength | 2 | 2015 | 332 | 0.110 |
Why?
| | Clinical Trials as Topic | 3 | 2024 | 1062 | 0.110 |
Why?
| | Health Policy | 1 | 2018 | 399 | 0.110 |
Why?
| | Nitric Oxide | 1 | 2020 | 883 | 0.110 |
Why?
| | Physical Conditioning, Human | 1 | 2015 | 38 | 0.110 |
Why?
| | Rituximab | 1 | 2016 | 208 | 0.110 |
Why?
| | Neuroendocrine Cells | 1 | 2015 | 34 | 0.110 |
Why?
| | Geographic Information Systems | 1 | 2014 | 45 | 0.110 |
Why?
| | Case-Control Studies | 4 | 2019 | 3633 | 0.100 |
Why?
| | Enzyme Inhibitors | 2 | 2016 | 820 | 0.100 |
Why?
| | Recovery of Function | 1 | 2018 | 721 | 0.100 |
Why?
| | Interviews as Topic | 2 | 2016 | 926 | 0.100 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2013 | 26 | 0.100 |
Why?
| | Societies, Medical | 5 | 2020 | 901 | 0.100 |
Why?
| | Sarcoidosis, Pulmonary | 1 | 2015 | 100 | 0.100 |
Why?
| | Sildenafil Citrate | 1 | 2013 | 60 | 0.100 |
Why?
| | Information Dissemination | 1 | 2016 | 224 | 0.100 |
Why?
| | Carbon Monoxide | 3 | 2019 | 82 | 0.100 |
Why?
| | Antifibrinolytic Agents | 1 | 2014 | 68 | 0.100 |
Why?
| | Sulfones | 1 | 2013 | 127 | 0.100 |
Why?
| | Endpoint Determination | 1 | 2013 | 84 | 0.090 |
Why?
| | Smoking | 3 | 2019 | 1478 | 0.090 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2013 | 43 | 0.090 |
Why?
| | Phenotype | 2 | 2018 | 3186 | 0.090 |
Why?
| | Predictive Value of Tests | 3 | 2024 | 2097 | 0.090 |
Why?
| | Purines | 1 | 2013 | 188 | 0.090 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1581 | 0.090 |
Why?
| | Patient Dropouts | 1 | 2013 | 65 | 0.090 |
Why?
| | Self Report | 2 | 2019 | 869 | 0.090 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2013 | 140 | 0.090 |
Why?
| | Health Care Surveys | 1 | 2014 | 538 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 1 | 2012 | 117 | 0.090 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2013 | 365 | 0.090 |
Why?
| | Occupational Exposure | 1 | 2016 | 356 | 0.090 |
Why?
| | Vasodilator Agents | 1 | 2013 | 326 | 0.090 |
Why?
| | Adaptation, Psychological | 1 | 2017 | 718 | 0.090 |
Why?
| | Consensus | 1 | 2013 | 465 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2018 | 942 | 0.090 |
Why?
| | Dust | 1 | 2012 | 92 | 0.090 |
Why?
| | Minnesota | 1 | 2012 | 167 | 0.090 |
Why?
| | Piperazines | 1 | 2013 | 367 | 0.080 |
Why?
| | United Kingdom | 1 | 2012 | 376 | 0.080 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2012 | 533 | 0.080 |
Why?
| | Fear | 1 | 2014 | 371 | 0.080 |
Why?
| | Epidemiologic Methods | 1 | 2010 | 91 | 0.080 |
Why?
| | Young Adult | 5 | 2017 | 14240 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2013 | 234 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 511 | 0.080 |
Why?
| | Clinical Competence | 1 | 2019 | 1261 | 0.080 |
Why?
| | Sickness Impact Profile | 2 | 2009 | 67 | 0.070 |
Why?
| | Salivary Glands, Minor | 1 | 2009 | 9 | 0.070 |
Why?
| | Pilot Projects | 2 | 2015 | 1878 | 0.070 |
Why?
| | Sjogren's Syndrome | 1 | 2009 | 31 | 0.070 |
Why?
| | Hyperplasia | 2 | 2015 | 164 | 0.070 |
Why?
| | International Cooperation | 3 | 2015 | 192 | 0.070 |
Why?
| | Risk | 1 | 2011 | 917 | 0.070 |
Why?
| | Scleroderma, Limited | 1 | 2008 | 5 | 0.070 |
Why?
| | Europe | 3 | 2015 | 420 | 0.070 |
Why?
| | Oximetry | 1 | 2009 | 124 | 0.070 |
Why?
| | Poisson Distribution | 3 | 2016 | 77 | 0.070 |
Why?
| | Radiography | 2 | 2016 | 856 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2011 | 569 | 0.060 |
Why?
| | Wound Healing | 1 | 2010 | 348 | 0.060 |
Why?
| | Comorbidity | 2 | 2017 | 1652 | 0.060 |
Why?
| | Mass Screening | 2 | 2026 | 1300 | 0.060 |
Why?
| | Sleep Wake Disorders | 1 | 2011 | 314 | 0.060 |
Why?
| | Pericardium | 1 | 2007 | 59 | 0.060 |
Why?
| | Models, Statistical | 1 | 2011 | 667 | 0.060 |
Why?
| | Depression | 2 | 2019 | 1566 | 0.060 |
Why?
| | Clinical Trials, Phase III as Topic | 2 | 2016 | 116 | 0.060 |
Why?
| | Seasons | 1 | 2008 | 535 | 0.060 |
Why?
| | Medical Records | 1 | 2006 | 190 | 0.060 |
Why?
| | Regression Analysis | 3 | 2016 | 994 | 0.060 |
Why?
| | Singapore | 1 | 2024 | 27 | 0.050 |
Why?
| | California | 1 | 2005 | 473 | 0.050 |
Why?
| | Echocardiography | 1 | 2007 | 645 | 0.050 |
Why?
| | Bronchoscopy | 1 | 2025 | 227 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2018 | 0.050 |
Why?
| | Acute Disease | 1 | 2006 | 1033 | 0.050 |
Why?
| | Data Interpretation, Statistical | 2 | 2018 | 365 | 0.050 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 147 | 0.050 |
Why?
| | ROC Curve | 1 | 2025 | 613 | 0.050 |
Why?
| | Terminology as Topic | 1 | 2005 | 253 | 0.050 |
Why?
| | Lymphoid Tissue | 1 | 2002 | 82 | 0.040 |
Why?
| | Rheumatologists | 1 | 2022 | 15 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2023 | 183 | 0.040 |
Why?
| | Exome | 1 | 2023 | 232 | 0.040 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 74 | 0.040 |
Why?
| | Age Factors | 3 | 2019 | 3321 | 0.040 |
Why?
| | Lysophospholipids | 1 | 2021 | 80 | 0.040 |
Why?
| | Patient Care | 1 | 2022 | 120 | 0.040 |
Why?
| | Patient Selection | 1 | 2005 | 720 | 0.040 |
Why?
| | Telomere | 1 | 2024 | 300 | 0.040 |
Why?
| | Attitude | 1 | 2022 | 253 | 0.040 |
Why?
| | Total Lung Capacity | 1 | 2019 | 29 | 0.040 |
Why?
| | Genomics | 1 | 2025 | 851 | 0.040 |
Why?
| | Occupations | 1 | 2019 | 50 | 0.040 |
Why?
| | Pulmonary Surfactant-Associated Protein A | 1 | 2019 | 30 | 0.040 |
Why?
| | Adolescent | 3 | 2017 | 22451 | 0.040 |
Why?
| | Pulmonary Surfactant-Associated Protein C | 1 | 2019 | 45 | 0.040 |
Why?
| | GTPase-Activating Proteins | 1 | 2019 | 81 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4565 | 0.040 |
Why?
| | Blood Gas Analysis | 1 | 2019 | 80 | 0.040 |
Why?
| | Exoribonucleases | 1 | 2019 | 48 | 0.030 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2019 | 115 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 2020 | 567 | 0.030 |
Why?
| | Education | 1 | 2018 | 102 | 0.030 |
Why?
| | DNA Helicases | 1 | 2019 | 138 | 0.030 |
Why?
| | Telomere-Binding Proteins | 1 | 2019 | 121 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2018 | 90 | 0.030 |
Why?
| | Administrative Claims, Healthcare | 1 | 2017 | 28 | 0.030 |
Why?
| | Forecasting | 1 | 2019 | 386 | 0.030 |
Why?
| | Physical Endurance | 1 | 2019 | 278 | 0.030 |
Why?
| | Telomerase | 1 | 2019 | 252 | 0.030 |
Why?
| | Mucin-5B | 1 | 2019 | 234 | 0.030 |
Why?
| | Hypersplenism | 1 | 2016 | 9 | 0.030 |
Why?
| | Spirometry | 1 | 2017 | 234 | 0.030 |
Why?
| | Leukopenia | 1 | 2016 | 33 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2019 | 771 | 0.030 |
Why?
| | Banking, Personal | 1 | 2016 | 2 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1843 | 0.030 |
Why?
| | Rheumatoid Factor | 1 | 2017 | 177 | 0.030 |
Why?
| | Health Care Sector | 1 | 2016 | 25 | 0.030 |
Why?
| | Creatine Kinase | 1 | 2016 | 70 | 0.030 |
Why?
| | Death Certificates | 1 | 2016 | 32 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 538 | 0.030 |
Why?
| | Social Participation | 1 | 2016 | 27 | 0.030 |
Why?
| | Arthritis | 1 | 2016 | 97 | 0.030 |
Why?
| | Biomarkers | 2 | 2019 | 4329 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2017 | 283 | 0.030 |
Why?
| | Commerce | 1 | 2016 | 80 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2016 | 142 | 0.030 |
Why?
| | Multiple Pulmonary Nodules | 1 | 2015 | 23 | 0.030 |
Why?
| | Metals | 1 | 2016 | 137 | 0.030 |
Why?
| | Anthropometry | 1 | 2015 | 203 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2019 | 1236 | 0.030 |
Why?
| | Physical Examination | 1 | 2016 | 236 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1700 | 0.030 |
Why?
| | Genetic Variation | 1 | 2019 | 992 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 777 | 0.030 |
Why?
| | Alberta | 1 | 2013 | 25 | 0.030 |
Why?
| | Bronchiolitis | 1 | 2015 | 87 | 0.020 |
Why?
| | Mortality, Premature | 1 | 2013 | 14 | 0.020 |
Why?
| | Adrenal Cortex Hormones | 1 | 2016 | 483 | 0.020 |
Why?
| | Teaching | 1 | 2016 | 243 | 0.020 |
Why?
| | Odds Ratio | 1 | 2016 | 1070 | 0.020 |
Why?
| | Counseling | 1 | 2016 | 403 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1034 | 0.020 |
Why?
| | RNA | 1 | 2019 | 925 | 0.020 |
Why?
| | Congresses as Topic | 1 | 2013 | 226 | 0.020 |
Why?
| | Genome-Wide Association Study | 1 | 2019 | 1526 | 0.020 |
Why?
| | Administration, Oral | 1 | 2014 | 867 | 0.020 |
Why?
| | Antigens, Human Platelet | 1 | 2011 | 10 | 0.020 |
Why?
| | Latin America | 1 | 2011 | 96 | 0.020 |
Why?
| | Japan | 1 | 2011 | 149 | 0.020 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2455 | 0.020 |
Why?
| | Alanine-tRNA Ligase | 1 | 2009 | 4 | 0.020 |
Why?
| | Threonine-tRNA Ligase | 1 | 2009 | 5 | 0.020 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2011 | 512 | 0.020 |
Why?
| | DNA Topoisomerases, Type I | 1 | 2008 | 15 | 0.020 |
Why?
| | Syndrome | 1 | 2009 | 377 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2015 | 2497 | 0.020 |
Why?
| | Animals | 1 | 2010 | 38030 | 0.020 |
Why?
| | Lymphocytes | 1 | 2009 | 379 | 0.020 |
Why?
| | Pulmonary Wedge Pressure | 1 | 2007 | 66 | 0.020 |
Why?
| | Body Mass Index | 1 | 2015 | 2446 | 0.010 |
Why?
| | Risk Assessment | 1 | 2015 | 3678 | 0.010 |
Why?
| | Muscle, Skeletal | 1 | 2015 | 1795 | 0.010 |
Why?
| | Nuclear Proteins | 1 | 2008 | 739 | 0.010 |
Why?
| | Child | 1 | 2002 | 22638 | 0.010 |
Why?
| | Pneumonia | 1 | 2008 | 633 | 0.010 |
Why?
|
|
Swigris's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|